| Bioactivity | Anticancer agent 241 (HZ1) is an orally active first-in-class cyclin-dependent kinase like 3 (CDKL3)-specific inhibitor. Anticancer agent 241 shows a strong tumor-suppressing effect, and has the potential to overcome the resistance of CDK4/6 inhibitor[1]. |
| Invitro | Anticancer agent 241 (HZ1；2-10 小时；100 nM) 显着降低 pRb 和 CDK4 的水平，从而有效触发细胞周期停滞和肿瘤死亡[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> HZ1 相关抗体: Western Blot Analysis[1] Cell Line: |
| In Vivo | Anticancer agent 241 (HZ1；1 mg/kg；口服管饲；每天 12-14 天) 在小鼠结肠癌模型中具有抗癌活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 3030492-40-8 |
| Formula | C20H22N6O |
| Molar Mass | 362.43 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Haijiao Zhang, et al. CDKL3 is a targetable regulator of cell cycle progression in cancers. J Clin Invest. 2024 Jul 4:e178428. |